Specialty Pharmacy Routing Proves Treatment Complexity in PI Cases

Amar Lunagaria — Co-Founder & Chief Pharmacist, LienScripts | March 4, 2026 | 7 min read

When a medication requires specialty pharmacy dispensing rather than a standard retail pharmacy, it documents that the treatment has reached a level of complexity requiring specialized handling, monitoring, and clinical oversight. Learn how specialty routing strengthens PI cases.

Specialty pharmacy routing -- when a medication must be dispensed through a specialty pharmacy rather than a standard retail pharmacy -- is an objective marker of treatment complexity that most attorneys never consider as evidence. Specialty pharmacies exist because certain medications require cold-chain storage, specialized reconstitution, injection training, enhanced clinical monitoring, or Risk Evaluation and Mitigation Strategy (REMS) compliance that standard retail pharmacies cannot provide. When a plaintiff's treatment reaches the point where prescriptions are routed to a specialty pharmacy, the healthcare system has classified the patient's condition as too complex for standard pharmaceutical care.

• Specialty pharmacy routing documents that the medication requires handling, monitoring, or clinical oversight beyond what retail pharmacies provide
• Medications requiring specialty dispensing are classified as high-complexity by the pharmacy industry and insurance companies independently
• LienScripts coordinates specialty pharmacy needs when required, and each case receives a MERIT (Medication Evaluation & Rationale for Injury Treatment) report that documents why specialty routing was clinically necessary
• REMS program medications routed through specialty pharmacies carry the FDA's own determination that the drug requires enhanced safety protocols due to its potency and risk profile
• The specialty classification is assigned by the pharmaceutical manufacturer, the FDA, and the insurance company -- three independent sources validating treatment complexity

What Makes a Medication "Specialty"

Specialty medications are distinguished from standard medications by one or more of the following characteristics:

Storage and Handling Requirements

• Cold-chain medications -- require refrigeration (2-8 degrees C) throughout the supply chain, from manufacturer to patient
• Light-sensitive medications -- must be stored in opaque containers and protected from UV exposure
• Reconstitution requirements -- must be mixed or prepared before administration, requiring pharmacist preparation

Administration Complexity

• Injectable medications -- self-administered subcutaneous or intramuscular injections requiring patient training
• Infusion medications -- intravenous administration requiring clinical setting and monitoring
• Specialized delivery devices -- auto-injectors, prefilled syringes, or infusion pumps requiring patient education

Clinical Monitoring Requirements

• Lab monitoring -- regular blood tests required to monitor for toxicity or therapeutic levels
• Clinical assessments -- periodic provider evaluations required as a condition of continued dispensing
• Adverse event reporting -- enhanced monitoring and reporting obligations under REMS

As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, "When a patient's medication is routed to a specialty pharmacy, the pharmaceutical supply chain itself has classified the treatment as high-complexity. This is not a subjective clinical opinion -- it is an objective system classification based on the medication's handling requirements, administration complexity, and monitoring needs. A plaintiff whose injury requires specialty pharmacy medications has a condition that the entire healthcare system recognizes as requiring a higher level of pharmaceutical care."

Specialty Routing as Severity Evidence

The Escalation Pathway

Most PI cases begin with standard retail pharmacy medications:

1. Initial treatment: NSAIDs, muscle relaxants, standard analgesics -- retail pharmacy
2. Intermediate treatment: Controlled substances, higher-tier medications -- retail pharmacy with monitoring
3. Advanced treatment: Specialty medications (biologics, CGRP inhibitors, specialty pain formulations) -- specialty pharmacy routing required

The transition from retail to specialty pharmacy documents that the patient's condition has progressed beyond what standard medications can manage. This escalation is verifiable through the dispensing pharmacy records, which identify the dispensing location as a specialty pharmacy.

Insurance Classification Validates Complexity

Insurance companies independently classify medications as "specialty" and route them to designated specialty pharmacies. This classification is based on:

• Clinical complexity -- the medication requires enhanced clinical oversight
• Cost threshold -- specialty medications typically exceed certain cost thresholds
• Distribution restrictions -- the manufacturer limits distribution to specialty channels

When an insurance company routes a medication to a specialty pharmacy, they have independently determined the treatment is too complex for standard dispensing -- a third-party validation of treatment complexity.

Common Specialty Medications in PI Cases

CGRP Inhibitors for Post-Traumatic Migraine

Medications like Aimovig (erenumab), Ajovy (fremanezumab), and Emgality (galcanezumab) are injectable biologics that require specialty pharmacy dispensing due to cold-chain storage and self-injection training requirements. Their use documents that the plaintiff's post-traumatic migraines are severe enough to require biologic therapy after failing oral preventive medications.

Specialty Pain Formulations

Certain pain management medications require specialty pharmacy routing due to REMS requirements, specialized monitoring, or restricted distribution. The routing itself documents the pain severity and treatment complexity.

Psychiatric Specialty Medications

Some psychiatric medications used for treatment-resistant PTSD or anxiety require specialty pharmacy dispensing due to monitoring requirements or REMS compliance.

Using Specialty Routing Evidence in Demand Packages

When presenting specialty pharmacy evidence in demand packages:

1. Identify specialty-dispensed medications -- flag every medication in the fill history that was dispensed by a specialty pharmacy
2. Explain why specialty routing was required -- document the specific storage, handling, administration, or monitoring requirements
3. Show the retail-to-specialty transition -- demonstrate that the patient progressed from standard to specialty medications as the condition's complexity increased
4. Reference manufacturer restrictions -- note when the manufacturer restricts distribution to specialty channels, validating that the classification is not discretionary
5. Document clinical monitoring -- include any lab work, assessments, or REMS compliance documentation that accompanied the specialty dispensing

LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report for every case, providing pharmacist-signed documentation for demand packages that includes specialty pharmacy routing analysis.

Countering Defense Arguments

"Standard medication would be sufficient."

If standard medications were sufficient, the prescriber would not have progressed to specialty medications. The escalation from retail to specialty pharmacy documents that standard options were tried and found insufficient. The specialty routing is the prescriber's and the healthcare system's determination that the condition requires advanced pharmacotherapy.

"Specialty medications are unnecessarily expensive."

Specialty medications are classified as such based on clinical complexity, not cost. The storage, handling, monitoring, and administration requirements exist because the medication's pharmacological profile demands them. The cost reflects the clinical complexity, not the other way around.

"The condition does not warrant this level of treatment."

The specialty classification is assigned by three independent authorities: the pharmaceutical manufacturer (restricted distribution), the FDA (REMS requirements), and the insurance company (specialty tier classification). All three determined the medication requires enhanced pharmaceutical care. Defense counsel would need to argue against all three to challenge the classification.

Practical Takeaways

Specialty pharmacy routing is an underrecognized marker of treatment complexity in PI cases. When a plaintiff's medication requires specialty pharmacy dispensing, the pharmaceutical supply chain, the FDA, and the insurance company have independently classified the treatment as high-complexity. Attorneys who present specialty routing evidence demonstrate that their client's condition has reached a severity level that the entire healthcare system recognizes as requiring advanced pharmaceutical care.

Related Resources

• REMS Program Medications as Extreme Severity Evidence -- FDA-mandated safety programs as severity indicators
• Co-Prescribed Medications Prove Injury Severity -- Multi-medication regimens and complexity
• Prior Authorization Denials as Severity Evidence -- Using insurance processes as evidence